Bupropion Hydrobromide Patent Expiration

Bupropion Hydrobromide is Used for treating major depressive disorder with once-daily dosing. It was first introduced by Bausch Health Us Llc in its drug Aplenzin on Apr 23, 2008.


Bupropion Hydrobromide Patents

Given below is the list of patents protecting Bupropion Hydrobromide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Aplenzin US7241805 Modified release formulations of a bupropion salt Jun 27, 2026 Bausch
Aplenzin US7569610 Modified release formulations of a bupropion salt Jun 27, 2026 Bausch
Aplenzin US7572935 Modified release formulations of a bupropion salt Jun 27, 2026 Bausch
Aplenzin US7585897 Modified release formulations of a bupropion salt Jun 27, 2026 Bausch
Aplenzin US7645802 Bupropion hydrobromide and therapeutic applications Jun 27, 2026 Bausch
Aplenzin US7649019 Modified release formulations of a bupropion salt Jun 27, 2026 Bausch
Aplenzin US7662407 Modified release formulations of a bupropion salt Jun 27, 2026 Bausch
Aplenzin US7671094 Bupropion hydrobromide and therapeutic applications Jun 27, 2026 Bausch



Bupropion Hydrobromide's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List